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Editorial
Somatostatin receptors became a model biological target for 
molecular imaging due to growing knowledge on their expression 
and due to the improved methods for their identification. The first 
synthetic somatostatin analogs were used in the clinics to control 
the symptoms of neuroendocrine tumors in the early 1980s. The 
first 111In-labeled somatostatin analog, 111In-pentetreotide, has been 
approved for use as a drug in 1995. Our experiences with the 
development of 99mTc-labeled somatostatin analogs date back 
to 1996 and were initiated within the International Atomic Energy 
Agency coordinated research project on “99mTc radiopharmaceu-
ticals for imaging of peripheral receptors” with the involvement of 
world class specialists in the field. The first-in-human diagnostic 
application of Somatostatin Receptor Scintigraphy (SRS) with 
99mTc-(tricine)HYNIC-TOC was published in 2000. Importantly, in 
the same period, the first patient images with the somatostatin 
analog, 99mTc-EDDA/HYNIC-Tyr3-octreotide, prepared from the dry 
kit formulation were acquired in Poland in the group of prof. Piotr 
Lass in Gdańsk. This new technique was further developed in clini-
cal centers in Warsaw, Łódź, Poznań and Kraków with the excellent 
publication record documenting the diagnostic value of SRS. The 
original proprietary name Tektrotyd was the result of stimulating 
discussions and guidance by prof. Julian Liniecki from Łódź. We 
regret that the small space of this editorial does not allow listing 
all those who contributed to the success of this new radiophar-
maceutical. Their pioneering work is now validated by Marketing 
Authorization of Tektrotyd in most of the European countries and 
by its expansion beyond Europe. 
In the current issue of Nuclear Medicine Review various as-
pects of SRS in diagnostics of neuroendocrine neoplasms (NEN) 
are presented and discussed. Several original papers report on 
the diagnostic utility of this method supported with images help-
ful in interpretation and in proper patient diagnosis. This chapter 
opens with the paper written by Polish colleagues who evalu-
ated the utility of peptide receptor scintigraphy with the use of 
99mTc-EDDA/HYNIC-TOC in the diagnosis of Iodine Avid Differen-
tiated Thyroid Cancer. The investigators from Croatia analyzed the 
usefulness of SRS with 99mTc-EDDA/HYNIC-TOC in patients with 
somatostatin receptor (SSTR) positive tumors of head and neck 
region. The experiences in imaging of bronchial and thymic neu-
roendocrine tumors were presented by authors from Bulgaria. 
Another article from Poland worked out the influence of PET/CT 
68Ga somatostatin receptor imaging on proceeding with patients, 
who were previously diagnosed using SPECT 99mTc-Tektrotyd. Based 
on the high number of performed SRS studies the colleagues from 
Hungary shared their observations with regard to the limitations and 
pitfalls of 99mTc-EDDA/HYNIC-TOC scintigraphy, a “must to know” to 
improve the diagnostic accuracy. The clinical part is closed with the 
overview of efficacy of this method in neuroendocrine neoplasms, 
provided by investigators from Serbia. Radiopharmaceutical de-
velopments and pre-clinical evaluation of Exendin-4, an agonist of 
GLP-1 receptor, are presented in another original paper coming from 
Poland. These receptors are expressed in high density in insulino-
mas, another diagnostically challenging neuroendocrine neoplasm. 
The Review part of this issue consists of three papers. The 
first two: “Neuroendocrine neoplasms and somatostatin receptor 
subtypes expression”, “NEN — the role of somatostatin receptor 
scintigraphy in clinical setting” — written by Polish authors. The 
introducing paper by Tomaszewska et al. presents the overview 
of somatostatin receptor expression in various tissues. The fol-
lowing one by Opalinska et al. discusses the role of somatostatin 
receptor imaging in NENs and opens the new perspectives, in 
particular offered by hybrid imaging PET/CT. The summary of ra-
diopharmaceutical developments and the new trends in design of 
radiopharmaceuticals for SSTR imaging, also in the context of new 
developments in imaging instrumentation has been presented by 
Mikolajczak and Maecke, the Polish and German authors. 
With this issue of Nuclear Medicine Review, thanks to the large 
number of interesting contributions resulting in the selection of 
original and review papers, the utility of SRS was demonstrated, not 
only in terms of neuroendocrine neoplasms visualization but also in 
terms of its extensive use in various regions of Europe.
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